For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 478.78% and ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo ...

A new study reveals that junk food and drug use are hindering life expectancy gains in the U.S., despite technological ...

Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just ...

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

What does the latest science say about the use of GLP-1 meds to treat obesity in people without diabetes?A review of 26 ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...